Nektar Announces Positive Results From Phase 2 Study Of Oral NKTR-118 In Patients With Opioid-Induced Constipation (OIC)
Nektar Therapeutics (Nasdaq: NKTR) announced positive topline results from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the most common and debilitating manifestation of opioid-bowel dysfunction (OBD).
Related Posts
Tags: constipation, induced, nektar, nktr, opioid, oral, patients, phase, positive, results, study
This entry was posted on Friday, March 6th, 2009 at 10:03 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



